Dr Mirren Mandalia, Senior Director of New Ventures & Transactions,
Johnson & Johnson Innovation
In November 2016, I welcomed the opportunity to attend the GIANT Health Event in London to present an overview of the Johnson & Johnson Innovation approach to supporting entrepreneurs and early stage companies in their healthcare business ventures. This is a subject I feel passionate about, and as a lead for investments for Johnson & Johnson Innovation in early stage medical devices and enabling technologies across Europe, the Middle East and Africa, it is something I can play a key role in. In particular, this means I see first-hand the positive impact collaborations such as these can have on the healthcare industry as a whole.
Innovation is at the heart of our business as we continually strive to help people live longer, healthier and happier lives. With over 130 years of healthcare breakthroughs, Johnson & Johnson has been at the forefront of some of the world’s most significant healthcare advancements. From first aid kits on the battlefield in the 1880s, to the first biologic for Crohn’s Disease and the first coronary and drug-eluting stents for coronary heart disease in the early 1990s.
However, it is important to point out that our success is by no means exclusively our own – external collaborative innovation is a key part of our long-term growth strategy. In order to actively improve people’s lives around the world, we recognise the need for new thinking and entrepreneurship in pharmaceuticals, medical devices and consumer products. We place a focus on supporting entrepreneurs and start-ups of all shapes and sizes to overcome the barriers they face in realising their ideas. In fact, Johnson & Johnson Innovation was conceived out of the need to address this and assist innovators in the research and development of transformative products and solutions.
Our Innovation Centres are strategically located in Boston, California, London and Shanghai within the world’s leading life science hotspots. Each Innovation Centre houses science and technology experts from across all three sectors of Johnson & Johnson, and has broad deal-making capabilities, with the flexibility to adapt deal structures depending on the needs of the company. Through this approach Johnson & Johnson Innovation is able to offer access to facilities including office space, lab space and capital equipment through our incubation centres, JLABS and JLINX, and access to Johnson & Johnson expertise such as R&D capabilities, regulatory and commercial expertise. With approximately 300 alliances in the past three years and plenty more on the horizon, we’re continuously striving to meet some of the many unmet needs.
By keeping innovation at the forefront of everything we do, our outputs reflect the ever-changing necessities of an evolving healthcare landscape. Ingrained in our DNA is the concept that a great idea can come from anywhere. Collaboration is the gateway to working with like-minded people to make lasting, transformative changes.